Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED
Phase III Results Said To Derisk VRDN-003
Results from the Phase III THRIVE trial in active thyroid eye disease had analysts calling veligrotug “best-in-class” as they anticipate results from THRIVE-2 in chronic TED later this year.
